Patent Law Weblog
recent posts
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
about
Month: November 2011
-
By Donald Zuhn — Last week, Sen. Jeff Bingaman (D-NM) introduced a bill in the Senate (S. 1882) that would eliminate the 180-day exclusivity period for a generic applicant that enters into a disqualifying agreement as defined by the legislation. In introducing the bill, also known as the "Fair And Immediate Release of Generic Drugs…
-
By Donald Zuhn — Earlier this month, the U.S. Food and Drug Administration announced that the agency has approved 35 new drugs over the past twelve months. With the exception of 2009, when 37 new drugs were approved, more drugs were approved in fiscal year (FY) 2011, which ended September 30, than in any other…
-
November 30 to December 1, 2011 – Advanced Forum on Biotech Patents*** (American Conference Institute) – Boston, MA December 1, 2011 – Biotechnology/Chemical/ Pharmaceutical (BCP) Customer Partnership Meeting (U.S. Patent and Trademark Office) – 9:00 am – 5:15 pm (ET) December 5, 2011 – 22nd Annual Conference on USPTO Law and Practice — PTO Day…
-
Birch, Stewart, Kolasch & Birch, LLP and CONNECT, a regional program that catalyzes the creation of innovative technology and life sciences products in San Diego County and has assisted in the formation and development of more than 3,000 companies, will be holding a public policy forum entitled "A Review of the America Invents Act and…
-
C5 (UK) will be holding its 4th Annual Pharma & Biotech Patent Litigation conference from January 31 to February 1, 2012 in Amsterdam, The Netherlands. At the conference, C5 faculty will offer presentations on the following topics: • Recent Case Law Developments in Pharma and Biotech Patent Litigation in Germany (keynote address);• SPC references and…
-
By Donald Zuhn — EPO, JPO, and USPTO Meet at Annual Trilateral Conference The European Patent Office, Japan Patent Office, and U.S. Patent and Trademark Office gathered last week at the 29th annual Trilateral Conference in St. Germain-en-Laye, France to discuss ways to further harmonize their patent systems. This year's conference focused on a number…
-
By Donald Zuhn — On Monday, Geron Corporation announced that it was discontinuing further development of its human embryonic stem cell (hESC) programs and would be seeking partners for each of the programs, which include oligodendrocyte progenitor cells (GRNOPC1) for central nervous system disorders, cardiomyocytes (GRNCM1) for heart disease, pancreatic islet cells (GRNIC1) for diabetes,…
-
By Huan Zhu — With recent developments in biotechnology, the legal issues surrounding its patent law since the 1980's have been a growing concern. Among all the subcategories of biotechnology, hESCs (human embryonic stem cells), one of the most controversial categories, is receiving different patent system treatments in different countries. The rules and regulations regarding…
-
By Kevin E. Noonan — In the aftermath of the European Court of Justice's decision last month that patent claims encompassing human embryonic stem cells (hESCs) were patent-ineligible in Europe on public order and morality grounds (see "European Court of Justice Renders Stem Cell Decision"), some commentators argued that the decision had a "silver lining": …
-
By Andrew Williams — In Streck, Inc. v. Research & Diagnostic Systems, Inc., the Federal Circuit clarified that when a party to an interference appeals the decision of the Board of Patent Appeals and Interferences to a district court in a civil action pursuant to 35 U.S.C. § 146, and new evidence is submitted, the…
Patent Docs 